Effect of nepafenac on the foveal profile of glaucomatous patients undergoing phacoemulsification
- PMID: 27771823
- DOI: 10.1007/s10792-016-0381-6
Effect of nepafenac on the foveal profile of glaucomatous patients undergoing phacoemulsification
Abstract
Purpose: Retrospective, pilot study to determine whether nepafenac treatment pre- and postcataract surgery in glaucoma patients using topical hypotensive agents minimized cystoid macular edema by comparing pre- and postsurgical foveal characteristics, as in some cases these agents cannot be withdrawn and, hypothetically, their inflammatory effect on the fovea could be neutralized by the addition of nepafenac.
Methods: Patients were divided into two subgroups depending on whether or not topical nepafenac was added to the surgical protocol (NEP = nepafenac group and nNEP = non nepafenac group). All had undergone phacoemulsification and data on pre- and postoperative macular status were recorded.
Results: In the nNEP group, there was a significant increase in foveal thickness (FT) in the first month postoperative visit with respect to the preoperative status (p = 0.006), and this situation did not change at the third postoperative month (p = 0.9411). In the NEP group, the increase in FT was not significant at the first month after surgery (p = 0.056) nor at the final visit (p = 0.268), in contrast to the nNEP group.
Conclusion: This study of the possible prophylactic effect of nepafenac on postoperative macular edema supports the results of other studies that confirm subclinical edema post phacoemulsification, and found a significantly lower gradient in the increase in FT in patients treated pre- and postoperatively with nepafenac.
Keywords: Cystoid macular edema; Hypotensive drugs; Nepafenac; Preservatives; Pseudophakic maculopathy.
Similar articles
-
Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification.J Cataract Refract Surg. 2012 Sep;38(9):1537-43. doi: 10.1016/j.jcrs.2012.04.034. Epub 2012 Jul 15. J Cataract Refract Surg. 2012. PMID: 22795976 Clinical Trial.
-
Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery.J Cataract Refract Surg. 2011 Sep;37(9):1581-8. doi: 10.1016/j.jcrs.2011.03.052. J Cataract Refract Surg. 2011. PMID: 21855758 Clinical Trial.
-
Intraindividual comparison of nepafenac 0.3% for the prevention of macular edema after phacoemulsification.J Cataract Refract Surg. 2018 Apr;44(4):440-446. doi: 10.1016/j.jcrs.2018.01.026. Epub 2018 Apr 22. J Cataract Refract Surg. 2018. PMID: 29685777 Clinical Trial.
-
Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac.Curr Med Res Opin. 2006 Feb;22(2):397-404. doi: 10.1185/030079906X89775. Curr Med Res Opin. 2006. PMID: 16466612 Review.
-
Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery.Ann Pharmacother. 2013 Jun;47(6):892-6. doi: 10.1345/aph.1R757. Epub 2013 May 28. Ann Pharmacother. 2013. PMID: 23715071 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical